Cargando…

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

SIMPLE SUMMARY: The prognostic impact of plasma protein biomarkers in breast cancer patients treated with neoadjuvant chemotherapy (NCT) was evaluated using a proteomics approach. Three biomarkers were identified among differentially expressed proteins. The plasma concentration of APOC3 was higher i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gwark, Sungchan, Ahn, Hee-Sung, Yeom, Jeonghun, Yu, Jiyoung, Oh, Yumi, Jeong, Jae Ho, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae, Lee, Hee Jin, Gong, Gyungyub, Lee, Sae Byul, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Son, Byung Ho, Ahn, Sei Hyun, Kim, Kyunggon, Kim, Jisun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699627/ https://www.ncbi.nlm.nih.gov/pubmed/34944885 http://dx.doi.org/10.3390/cancers13246267

Ejemplares similares

Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021)

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Generating Detailed Spectral Libraries for Canine Proteomes Obtained from Serum and Urine
por: Ahn, Hee-Sung, et al.
Publicado: (2023)

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2020)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Publisher Correction: Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2021)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2014)

Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
por: Lee, Sae Byul, et al.
Publicado: (2021)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
por: Yoo, Changhoon, et al.
Publicado: (2012)

Non-sentinel node metastasis prediction during surgery in breast cancer patients with one to three positive sentinel node(s) following neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2023)

Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155
por: Kim, Sinae, et al.
Publicado: (2021)

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks
por: Kim, Eun Young, et al.
Publicado: (2020)

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
por: Lee, Hee Jin, et al.
Publicado: (2015)

Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

Differential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer
por: Kim, Hakyoung, et al.
Publicado: (2023)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution’s experience
por: Alqudaihi, Heba Mohammad Abdulla, et al.
Publicado: (2022)

MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy
por: Ko, Beom Seok, et al.
Publicado: (2019)

A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation
por: Kim, Soo Han, et al.
Publicado: (2021)

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers
por: Ahn, Hee-Sung, et al.
Publicado: (2021)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023)

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
por: Lee, Sae Byul, et al.
Publicado: (2018)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study
por: Kim, Hakyoung, et al.
Publicado: (2022)

No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery
por: Yoon, Tae In, et al.
Publicado: (2018)

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Lee, Hee Jin, et al.
Publicado: (2013)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2018)

Salivary Duct Cancer Metastasis Mimicking Primary Breast Cancer: A Case Report and Review
por: Alzuhair, Aisha M., et al.
Publicado: (2019)

Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence
por: Baek, Soo Yeon, et al.
Publicado: (2022)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
por: Shin, Junyoung, et al.
Publicado: (2023)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype
por: Lee, Young-jin, et al.
Publicado: (2023)

Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Hwang, Young Sol, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f124a3uqioo4rsvmsqn9kv0ts6